Functional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4

Advances in Cancer Research

Volumn 109, Issue C, 2010, Pages 73-121

  Campoli, Michael ^a   Ferrone, Soldano ^b,c   Wang, Xinhui ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AN2; Angiogenesis; BFGF; Cancer stem cells; Collagen; CSPG4; HMW MAA; Immunotherapy; Integrin; Invasion; Matrix metalloproteinase; MCSP; Melanoma; Melanoma chondroitin sulfate proteoglycan; Metastasis; Migration; Monoclonal antibody; NG2; Oligodendrocyte; PDGF AA; Pericyte; Signal transduction; Stem cell

Indexed keywords

CHONDROITIN SULFATE; CHONDROITIN SULFATE PROTEOGLYCAN 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; BOOK; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; HUMAN; IMMUNOTHERAPY; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; T LYMPHOCYTE;

EID: 78149369920     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380890-5.00003-X     Document Type: Chapter

References (188)

1. Alexandrescu D.T., Ichim T.E., Riordan N.H., Marincola F.M., Di Nardo A., Kabigting F.D., Dasanu C.A. Immunotherapy for melanoma: Current status and perspectives. J. Immunother. 2010, 33:570-590.
2. Asher R.A., Morgenstern D.A., Properzi F., Nishiyama A., Levine J.M., Fawcett J.W. Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro. Mol. Cell. Neurosci. 2005, 29:82-96.
3. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17:2105-2116.
4. Barnhill R.L., Gupta K. Unusual variants of malignant melanoma. Clin. Dermatol. 2009, 27:564-587.
5. Barritt D.S., Pearn M.T., Zisch A.H., Lee S.S., Javier R.T., Pasquale E.B., Stallcup W.B. The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. J. Cell. Biochem. 2000, 79:213-224.
6. Basak S., Birebent B., Purev E., Somasundaram R., Maruyama H., Zaloudik J., Swoboda R., Strittmatter W., Li W., Luckenbach A., Song H., Li J., et al. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol. Immunother. 2003, 52:145-154.
7. Behm F.G., Smith F.O., Raimondi S.C., Pui C.H., Bernstein I.D. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996, 87:1134-1139.
8. Benassi M.S., Pazzaglia L., Chiechi A., Alberghini M., Conti A., Cattaruzza S., Wassermann B., Picci P., Perris R. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J. Orthop. Res. 2009, 27:135-140.
9. Bender H., Grapow M., Schomburg A., Reinhold U., Biersack H.J. Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. Hybridoma 1997, 16:65-68.
10. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
11. Bluemel C., Hausmann S., Fluhr P., Sriskandarajah M., Stallcup W.B., Baeuerle P.A., Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol. Immunother. 2010, 59:1197-1209.
12. Boiko A.D., Razorenova O.V., van de Rijn M., Swetter S.M., Johnson D.L., Ly D.P., Butler P.D., Yang G.P., Joshua B., Kaplan M.J., Longaker M.T., Weissman I.L. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
13. Bokoch G.M. Biology of the p21-activated kinases. Annu. Rev. Biochem. 2003, 72:743-781.
14. Bomanji J., Garner A., Prasad J., Albert D.M., Hungerford J.L., Granowska M., Britton K.E. Characterisation of ocular melanoma with cutaneous melanoma antibodies. Br. J. Ophthalmol. 1987, 71:647-650.
15. Borkhardt A., Wuchter C., Viehmann S., Pils S., Teigler-Schlegel A., Stanulla M., Zimmermann M., Ludwig W.D., Janka-Schaub G., Schrappe M., Harbott J. Infant acute lymphoblastic leukemia-Combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 2002, 16:1685-1690.
16. Bosco E.E., Mulloy J.C., Zheng Y. Rac1 GTPase: A "Rac" of all trades. Cell. Mol. Life Sci. 2009, 66:370-374.
17. Bumol T.F., Walker L.E., Reisfeld R.A. Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. J. Biol. Chem. 1984, 259:12733-12741.
18. Burg M.A., Grako K.A., Stallcup W.B. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol. 1998, 177:299-312.
19. Burg M.A., Tillet E., Timpl R., Stallcup W.B. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem. 1996, 271:26110-26116.
20. Campoli M., Ferrone S. Immunotherapy of malignant disease: The coming age of therapeutic monoclonal antibodies. Cancer: Principles & Practice of Oncology 2009, Vol 23:1-18. Lippincott Williams and Wilkins, New York, NY. V. DeVita, S. Hellman, S. Rosenberg (Eds.).
21. Campoli M., Chang C.C., Kageshita T., Wang X., McCarthy J.B., Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 2004, 24:267-296.
22. Campoli M., Ferris R., Ferrone S., Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin. Cancer Res. 2010, 16:11-20.
23. Cascinelli N., Santinami M., Maurichi A., Patuzzo R., Pennacchioli E. World Health Organization experience in the treatment of melanoma. Surg. Clin. North Am. 2003, 83:405-416.
24. Cha E., Fong L. Therapeutic vaccines for prostate cancer. Curr. Opin. Mol. Ther. 2010, 12:77-85.
25. Challier J.C., Carbillon L., Kacemi A., Vervelle C., Bintein T., Galtier M., Espie M.J., Uzan S. Characterization of first trimester human fetal placental vessels using immunocytochemical markers. Cell. Mol. Biol. (Noisy-le-grand) 2001, 47. 47, Online Pub, OL79-87. [Epub ahead of print].
26. Chatterjee N., Stegmuller J., Schatzle P., Karram K., Koroll M., Werner H.B., Nave K.A., Trotter J. Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells. J. Biol. Chem. 2008, 283:8310-8317.
27. Chattopadhyay P., Starkey J., Morrow W.J., Raychaudhuri S. Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA 1992, 89:2684-2688.
28. Chekenya M., Hjelstuen M., Enger P.O., Thorsen F., Jacob A.L., Probst B., Haraldseth O., Pilkington G., Butt A., Levine J.M., Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 2002, 16:586-588.
29. Clauss G., Lohmeyer J., Hamby C.V., Ferrone S., Anders F. Melanoma associated antigens in Xiphophorus Fish. Human Melanoma: From Basic Research to Clinical Application 1990, 74-86. Springer Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong. S. Ferrone (Ed.).
30. Cooper J.S. Radiation therapy of malignant melanoma. Dermatol. Clin. 2002, 20:713-716. x.
31. Cox B.D., Natarajan M., Stettner M.R., Gladson C.L. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J. Cell. Biochem. 2006, 99:35-52.
32. Crabbe T., Ioannou C., Docherty A.J. Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur. J. Biochem. 1993, 218:431-438.
33. Crosby T., Mason M., Crosby D. Malignant melanoma: Non-metastatic. Clin. Evid. 2001, 1175-1182. BMJ Publishing Group, London.
34. de Castro R., Tajrishi R., Claros J., Stallcup W.B. Differential responses of spinal axons to transection: Influence of the NG2 proteoglycan. Exp. Neurol. 2005, 192:299-309.
35. de Vries J.E., Keizer G.D., te Velde A.A., Voordouw A., Ruiter D., Rumke P., Spits H., Figdor C.G. Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int. J. Cancer 1986, 38:465-473.
36. Defilippi P., Di Stefano P., Cabodi S. p130Cas: A versatile scaffold in signaling networks. Trends Cell Biol. 2006, 16:257-263.
37. Desai S.A., Wang X., Noronha E.J., Kageshita T., Ferrone S. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res. 1998, 58:2417-2425.
38. Diers-Fenger M., Kirchhoff F., Kettenmann H., Levine J.M., Trotter J. AN2/NG2 protein-expressing glial progenitor cells in the murine CNS: Isolation, differentiation, and association with radial glia. Glia 2001, 34:213-228.
39. Dillman R.O. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin. Oncol. 2003, 30:434-447.
40. Drake A.S., Brady M.T., Wang X.H., Sait S.J., Earp J.C., Ghoshal Gupta S., Ferrone S., Wang E.S., Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunol. Immunother. 2009, 58:415-427.
41. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
42. Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.L., Tachibana K., Lim L., Manser E., Furcht L.T., Iida J. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat. Cell Biol. 1999, 1:507-513.
43. Erfurt C., Sun Z., Haendle I., Schuler-Thurner B., Heirman C., Thielemans K., van der Bruggen P., Schuler G., Schultz E.S. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J. Immunol. 2007, 178:7703-7709.
44. Erfurt C., Muller E., Emmerling S., Klotz C., Hertl M., Schuler G., et al. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients. Int. J. Cancer. 2009, 124:2341-2346.
45. Fang X., Burg M.A., Barritt D., Dahlin-Huppe K., Nishiyama A., Stallcup W.B. Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol. Biol. Cell 1999, 10:3373-3387.
46. Ferris R.L., Jaffee E.M., Ferrone S. Tumor antigen-targeted monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 2010, [Epub ahead of print].
47. Ferrone S., Chen Z.J., Liu C.C., Hirai S., Kageshita T., Mittelman A. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. Pharmacol. Ther. 1993, 57:259-290.
48. Ferrone S., Giacomini P., Natali P.G., Ruiter D., Buraggi G., Callegaro L., Rosa U. A human high molecular weight melanoma associated antigen (HMW MAA) defined by monoclonal antibodies: A useful marker to radioimage tumor lesions in patients with melanoma. Proc. 1st Int. Symp. on Neutron Capture Therapy 1983, 178-183. Brookhaven National Laboratory, Associated Universities, Inc.
49. Flaherty K.T., Hodi F.S., Bastian B.C. Mutation-driven drug development in melanoma. Curr. Opin. Oncol. 2010, 22:178-183.
50. Fletcher S., Drewry J.A., Shahani V.M., Page B.D., Gunning P.T. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 2009, 87:825-833.
51. Forstpointner R., Dreyling M., Repp R., Hermann S., Hanel A., Metzner B., Pott C., Hartmann F., Rothmann F., Rohrberg R., Bock H.P., Wandt H., Unterhalt M., Hiddemann W. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
52. Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D., Doeing C., Sayegh M.H., Frank M.H. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 2003, 278:47156-47165.
53. Fukushi J., Makagiansar I.T., Stallcup W.B. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol. Biol. Cell 2004, 15:3580-3590.
54. Garrigues H.J., Lark M.W., Lara S., Hellstrom I., Hellstrom K.E., Wight T.N. The melanoma proteoglycan: Restricted expression on microspikes, a specific microdomain of the cell surface. J. Cell Biol. 1986, 103:1699-1710.
55. Ghali L., Wong S.T., Tidman N., Quinn A., Philpott M.P., Leigh I.M. Epidermal and hair follicle progenitor cells express melanoma-associated chondroitin sulfate proteoglycan core protein. J. Invest. Dermatol. 2004, 122:433-442.
56. Ghesani M., Belgraier A., Hasni S. Carcinoembryonic antigen (CEA) scan in the diagnosis of recurrent colorectal carcinoma in a patient with increasing CEA levels and inconclusive computed tomographic findings. Clin. Nucl. Med. 2003, 28:608-609.
57. Giacomini P., Aguzzi A., Pestka S., Fisher P.B., Ferrone S. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. J. Immunol. 1984, 133:1649-1655.
58. Giubellino A., Burke T.R., Bottaro D.P. Grb2 signaling in cell motility and cancer. Expert Opin. Ther. Targets 2008, 12:1021-1033.
59. Goretzki L., Burg M.A., Grako K.A., Stallcup W.B. High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J. Biol. Chem. 1999, 274:16831-16837.
60. Goto Y., Arigami T., Murali R., Scolyer R.A., Tanemura A., Takata M., Turner R.R., Nguyen L., Nguyen T., Morton D.L., Ferone S., Hoon D.S. High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res. 2010, 23:137-140.
61. Grako K.A., Stallcup W.B. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp. Cell Res. 1995, 221:231-240.
62. Grako K.A., Ochiya T., Barritt D., Nishiyama A., Stallcup W.B. PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J. Cell Sci. 1999, 112(Pt 6):905-915.
63. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21:11-19.
64. Guerry D. The cellular immunobiology of melanoma. Cutaneous oncology: Pathophysiology, diagnosis, and management 1998, 211-217. Blackwell Science, Malden. S. Miller, M. Maloney (Eds.).
65. Harper J.R., Reisfeld R.A. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J. Natl. Cancer Inst. 1983, 71:259-263.
66. Hilden J.M., Smith F.O., Frestedt J.L., McGlennen R., Howells W.B., Sorensen P.H., Arthur D.C., Woods W.G., Buckley J., Bernstein I.D., Kersey J.H. MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 1997, 89:3801-3805.
67. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:779-781.
68. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
69. Huveneers S., Danen E.H. Adhesion signaling: Crosstalk between integrins, Src and Rho. J. Cell Sci. 2009, 122:1059-1069.
70. Iida J., Meijne A.M., Knutson J.R., Furcht L.T., McCarthy J.B. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin. Cancer Biol. 1996, 7:155-162.
71. Iida J., Meijne A.M., Oegema T.R., Yednock T.A., Kovach N.L., Furcht L.T., McCarthy J.B. A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. J. Biol. Chem. 1998, 273:5955-5962.
72. Iida J., Meijne A.M., Spiro R.C., Roos E., Furcht L.T., McCarthy J.B. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res. 1995, 55:2177-2185.
73. Iida J., Pei D., Kang T., Simpson M.A., Herlyn M., Furcht L.T., McCarthy J.B. Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J. Biol. Chem. 2001, 276:18786-18794.
74. Iida J., Skubitz A.P., Furcht L.T., Wayner E.A., McCarthy J.B. Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J. Cell Biol. 1992, 118:431-444.
75. Imai K., Pellegrino M.A., Wilson B.S., Ferrone S. Higher cytolytic efficiency of an IgG2 alpha than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. Cell. Immunol. 1982, 72:239-247.
76. Iyengar P., Espina V., Williams T.W., Lin Y., Berry D., Jelicks L.A., Lee H., Temple K., Graves R., Pollard J., Chopra N., Russell R.G., et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest. 2005, 115:1163-1176.
77. Jones L.L., Yamaguchi Y., Stallcup W.B., Tuszynski M.H. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J. Neurosci. 2002, 22:2792-2803.
78. Kageshita T., Kimura T., Yoshi A., Hirai S., Ono T., Ferrone S. Antigenic profile of mucosal melanoma lesions. Int. J. Cancer 1994, 56:370-374.
79. Kageshita T., Kuriya N., Ono T., Horikoshi T., Takahashi M., Wong G.Y., Ferrone S. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res. 1993, 53:2830-2833.
80. Kageshita T., Nakamura T., Yamada M., Kuriya N., Arao T., Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res. 1991, 51:1726-1732.
81. Kang N., Hamilton S., Odili J., Wilson G., Kupsch J. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Clin. Cancer Res. 2000, 6:4921-4931.
82. Kang N.V., Hamilton S., Sanders R., Wilson G.D., Kupsch J.M. Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments. Melanoma Res. 1999, 9:545-556.
83. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
84. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996, 14:7-17.
85. Kirsch M., Schackert G., Black P.M. Metastasis and angiogenesis. Cancer Treat. Res. 2004, 117:285-304.
86. Kitago M., Koyanagi K., Nakamura T., Goto Y., Faries M., O'Day S.J., Morton D.L., Ferrone S., Hoon D.S. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 2009, 55:757-764.
87. Klein W.M., Wu B.P., Zhao S., Wu H., Klein-Szanto A.J., Tahan S.R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20:102-107.
88. Knutson J.R., Iida J., Fields G.B., McCarthy J.B. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol. Biol. Cell 1996, 7:383-396.
89. Kose O., Lalli A., Kutulola A.O., Odell E.W., Waseem A. Changes in the expression of stem cell markers in oral lichen planus and hyperkeratotic lesions. J. Oral Sci. 2007, 49:133-139.
90. Kozanoglu I., Boga C., Ozdogu H., Sozer O., Maytalman E., Yazici A.C., Sahin F.I. Human bone marrow mesenchymal cells express NG2: Possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification. Cytotherapy 2009, 11:527-533.
91. Kraal G., Mebius R.E. High endothelial venules: Lymphocyte traffic control and controlled traffic. Adv. Immunol. 1997, 65:347-395.
92. Kusama M., Kageshita T., Chen Z.J., Ferrone S. Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J. Immunol. 1989, 143:3844-3852.
93. Larsen P.H., Wells J.E., Stallcup W.B., Opdenakker G., Yong V.W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 2003, 23:11127-11135.
94. Larson S.M., Carrasquillo J.A., McGuffin R.W., Krohn K.A., Ferens J.M., Hill L.D., Beaumier P.L., Reynolds J.C., Hellstrom K.E., Hellstrom I. Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience. Radiology 1985, 155:487-492.
95. Lee H., Pal S.K., Reckamp K., Figlin R.A., Yu H. STAT3: A target to enhance antitumor immune response. Curr. Top. Microbiol. Immunol. 2010, [Epub ahead of print].
96. Legg J., Jensen U.B., Broad S., Leigh I., Watt F.M. Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis. Development 2003, 130:6049-6063.
97. Li Y., Madigan M.C., Lai K., Conway R.M., Billson F.A., Crouch R., Allen B.J. Human uveal melanoma expresses NG2 immunoreactivity. Br. J. Ophthalmol. 2003, 87:629-632.
98. Liao S.K., Smith J.W., Kwong P.C., Natali P.G., Kusama M., Hamby C.V., Ferrone S. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells. Cancer Res. 1987, 47:4835-4841.
99. Lin T.S., Lucas M.S., Byrd J.C. Rituximab in B-cell chronic lymphocytic leukemia. Semin. Oncol. 2003, 30:483-492.
100. Lin X.H., Dahlin-Huppe K., Stallcup W.B. Interaction of the NG2 proteoglycan with the actin cytoskeleton. J. Cell. Biochem. 1996, 63:463-477.
101. Liu D., Sy M.S. A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid. J. Exp. Med. 1996, 183:1987-1994.
102. Liu S., Calderwood D.A., Ginsberg M.H. Integrin cytoplasmic domain-binding proteins. J. Cell Sci. 2000, 113(Pt 20):3563-3571.
103. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007, 23:675-699.
104. Lundell B.I., McCarthy J.B., Kovach N.L., Verfaillie C.M. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia 1997, 11:822-829.
105. Luo W., Hsu J.C., Tsao C.Y., Ko E., Wang X., Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J. Immunol. 2005, 174:7104-7110.
106. Luo W., Ko E., Hsu J.C., Wang X., Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: Functional effects. J. Immunol. 2006, 176:6046-6054.
107. Maciag P.C., Seavey M.M., Pan Z.K., Ferrone S., Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008, 68:8066-8075.
108. MacKie R.M., Hauschild A., Eggermont A.M. Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 2009, 20(Suppl. 6). vi1-7.
109. Maio M., Gulwani B., Morgano A., Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int. J. Cancer 1989, 44:554-559.
110. Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T., Stallcup W.B. Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J. Biol. Chem. 2004, 279:55262-55270.
111. Makagiansar I.T., Williams S., Mustelin T., Stallcup W.B. Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J. Cell Biol. 2007, 178:155-165.
112. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv. Immunol. 2000, 74:181-273.
113. Matsui M., Nakanishi T., Noguchi T., Imai K., Yachi A., Ferrone S. Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin. Jpn J. Cancer Res. 1985, 76:119-123.
114. Mauvieux L., Delabesse E., Bourquelot P., Radford-Weiss I., Bennaceur A., Flandrin G., Valensi F., MacIntyre E.A. NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Br. J. Haematol. 1999, 107:674-676.
115. Midwood K.S., Salter D.M. Expression of NG2/human melanoma proteoglycan in human adult articular chondrocytes. Osteoarthr. Cartil. 1998, 6:297-305.
116. Milstein C., Waldmann H. Optimism after much pessimism: What next?. Curr. Opin. Immunol. 1999, 11:589-591.
117. Mitchison T.J. Actin based motility on retraction fibers in mitotic PtK2 cells. Cell Motil. Cytoskeleton 1992, 22:135-151.
118. Mittelman A., Chen Z.J., Liu C.C., Hirai S., Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res. 1994, 54:415-421.
119. Mittelman A., Chen Z.J., Yang H., Wong G.Y., Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA 1992, 89:466-470.
120. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., Gritti A., Piccinini A., Porro D., Santinami M., Invernici G., Parati E., Alessandri G., La Porta C.A. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43:935-946.
121. Morgan A.C., Bordonaro J., Pearson J.W., Sivam G. Immunotoxins to a human melanoma-associated antigen: Resistance to pokeweed antiviral protein conjugates in vitro. J. Natl. Cancer Inst. 1987, 78:1101-1106.
122. Murray J.L., Gillogly M., Kawano K., Efferson C.L., Lee J.E., Ross M., Wang X., Ferrone S., Ioannides C.G. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res. 2004, 64:5481-5488.
123. Nagaiah G., Abraham J. Circulating tumor cells in the management of breast cancer. Clin. Breast Cancer 2010, 10:209-216.
124. Natali P.G., Giacomini P., Russo C., Steinbach G., Fenoglio C., Ferrone S. Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. J Cutan Pathol. 1983, 10:225-237.
125. Natali P.G., Imai K., Wilson B.S., Bigotti A., Cavaliere R., Pellegrino M.A., Ferrone S. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J. Natl. Cancer Inst. 1981, 67:591-601.
126. Nishi H., Inoue Y., Kageshita T., Takata M., Ihn H. The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma. Biosci. Trends 2010, 4:86-89.
127. Nishiyama A., Lin X.H., Stallcup W.B. Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Mol. Biol. Cell 1995, 6:1819-1832.
128. Nishiyama A., Lin X.H., Giese N., Heldin C.H., Stallcup W.B. Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J. Neurosci. Res. 1996, 43:315-330.
129. Ozerdem U., Grako K.A., Dahlin-Huppe K., Monosov E., Stallcup W.B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 2001, 222:218-227.
130. Parsons J.T. Focal adhesion kinase: The first ten years. J. Cell Sci. 2003, 116:1409-1416.
131. Paul A.K., Ciesielski M.J., Sajjad M., Wang X., Ferrone S., Abdel-Nabi H., Fenstermaker R.A. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: Potential for radioimmunotargeting. J. Neurooncol. 2009, 94:21-30.
132. Petrini S., Tessa A., Carrozzo R., Verardo M., Pierini R., Rizza T., Bertini E. Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies. Mol. Cell Neurosci. 2003, 23:219-231.
133. Piche B., Li G. Inhibitor of growth tumor suppressors in cancer progression. Cell. Mol. Life Sci. 2010, 67:1987-1999.
134. Pierce K.L., Luttrell L.M., Lefkowitz R.J. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001, 20:1532-1539.
135. Pluschke G., Vanek M., Evans A., Dittmar T., Schmid P., Itin P., Filardo E.J., Reisfeld R.A. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. USA 1996, 93:9710-9715.
136. Polette M., Birembaut P. Membrane-type metalloproteinases in tumor invasion. Int. J. Biochem. Cell Biol. 1998, 30:1195-1202.
137. Pouly S., Becher B., Blain M., Antel J.P. Expression of a homologue of rat NG2 on human microglia. Glia 1999, 27:259-268.
138. Pride M.W., Shuey S., Grillo-Lopez A., Braslawsky G., Ross M., Legha S.S., Eton O., Buzaid A., Ioannides C., Murray J.L. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin. Cancer Res. 1998, 4:2363-2370.
139. Ranson M., Andronicos N.M. Plasminogen binding and cancer: Promises and pitfalls. Front. Biosci. 2003, 8:s294-s304.
140. Raptis L., Arulanandam R., Vultur A., Geletu M., Chevalier S., Feracci H. Beyond structure, to survival: Activation of Stat3 by cadherin engagement. Biochem. Cell Biol. 2009, 87:835-843.
141. Reisfeld R.A., Cheresh D.A. Human tumor antigens. Adv. Immunol. 1987, 40:323-377.
142. Ribas A., Butterfield L.H., Glaspy J.A., Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 2003, 21:2415-2432.
143. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
144. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009, 21:233-240.
145. Ross A.H., Cossu G., Herlyn M., Bell J.R., Steplewski Z., Koprowski H. Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch. Biochem. Biophys. 1983, 225:370-383.
146. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., Fuhlbrigge R.C., Kupper T.S., Sayegh M.H., Frank M.H. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
147. Schlingemann R.O., Rietveld F.J., de Waal R.M., Ferrone S., Ruiter D.J. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J. Pathol. 1990, 136:1393-1405.
148. Schlingemann R.O., Rietveld F.J., Kwaspen F., van de Kerkhof P.C., de Waal R.M., Ruiter D.J. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am. J. Pathol. 1991, 138:1335-1347.
149. Schneider S., Bosse F., D'Urso D., Muller H., Sereda M.W., Nave K., Niehaus A., Kempf T., Schnolzer M., Trotter J. The AN2 protein is a novel marker for the Schwann cell lineage expressed by immature and nonmyelinating Schwann cells. J. Neurosci. 2001, 21:920-933.
150. Schon M., Schon M.P., Kuhrober A., Schirmbeck R., Kaufmannn R., Klein C.E. Expression of the human alpha2 integrin subunit in mouse melanoma cells confers the ability to undergo collagen-directed adhesion, migration and matrix reorganization. J. Invest. Dermatol. 1996, 106:1175-1181.
151. Schroff R.W., Foon K.A., Beatty S.M., Oldham R.K., Morgan A.C. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985, 45:879-885.
152. Schwab J.H., Boland P.J., Agaram N.P., Socci N.D., Guo T., O'Toole G.C., Wang X., Ostroumov E., Hunter C.J., Block J.A., Doty S., Ferrone S., Healey J.H., Antonescu C.R. Chordoma and chondrosarcoma gene profile: Implications for immunotherapy. Cancer Immunol. Immunother. 2009, 58:339-349.
153. Schwartz S., Rieder H., Schlager B., Burmeister T., Fischer L., Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: Close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype. Leukemia 2003, 17:1589-1595.
154. Shackleton M., Quintana E. Progress in understanding melanoma propagation. Mol. Oncol. 2010, [Epub ahead of print].
155. Sheetz M.P. Cell migration by graded attachment to substrates and contraction. Semin. Cell Biol. 1994, 5:149-155.
156. Sieg D.J., Hauck C.R., Ilic D., Klingbeil C.K., Schaefer E., Damsky C.H., Schlaepfer D.D. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2000, 2:249-256.
157. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
158. Smith F.O., Rauch C., Williams D.E., March C.J., Arthur D., Hilden J., Lampkin B.C., Buckley J.D., Buckley C.V., Woods W.G., Dinndorf P.A., Sorensen P., Kersey J., Hammond D., Bernstein I.D. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996, 87:1123-1133.
159. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
160. Spiro R.C., Freeze H.H., Sampath D., Garcia J.A. Uncoupling of chondroitin sulfate glycosaminoglycan synthesis by brefeldin A. J. Cell Biol. 1991, 115:1463-1473.
161. Spitler L.E., del Rio M., Khentigan A., Wedel N.I., Brophy N.A., Miller L.L., Harkonen W.S., Rosendorf L.L., Lee H.M., Mischak R.P., et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 1987, 47:1717-1723.
162. Stallcup W.B. The NG2 proteoglycan: Past insights and future prospects. J. Neurocytol. 2002, 31:423-435.
163. Stallcup W.B., Huang F.J. A role for the NG2 proteoglycan in glioma progression. Cell Adh. Migr. 2008, 2:192-201.
164. Staub E., Hinzmann B., Rosenthal A. A novel repeat in the melanoma-associated chondroitin sulfate proteoglycan defines a new protein family. FEBS Lett. 2002, 527:114-118.
165. Stegmuller J., Schneider S., Hellwig A., Garwood J., Trotter J. AN2, the mouse homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration. J. Neurocytol. 2002, 31:497-505.
166. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev. Cancer 2002, 2:514-520.
167. Terada N., Ohno N., Murata S., Katoh R., Stallcup W.B., Ohno S. Immunohistochemical study of NG2 chondroitin sulfate proteoglycan expression in the small and large intestines. Histochem. Cell Biol. 2006, 126:483-490.
168. Terando A., Sabel M.S., Sondak V.K. Melanoma: Adjuvant therapy and other treatment options. Curr. Treat. Options Oncol. 2003, 4:187-199.
169. Tillet E., Ruggiero F., Nishiyama A., Stallcup W.B. The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J. Biol. Chem. 1997, 272:10769-10776.
170. Timpl R., Tisi D., Talts J.F., Andac Z., Sasaki T., Hohenester E. Structure and function of laminin LG modules. Matrix Biol. 2000, 19:309-317.
171. Tordsson J.M., Ohlsson L.G., Abrahmsen L.B., Karlstrom P.J., Lando P.A., Brodin T.N. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Cancer Immunol. Immunother. 2000, 48:691-702.
172. Tsujisaki M., Igarashi M., Sakaguchi K., Eisinger M., Herlyn M., Ferrone S. Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J. Immunol. 1987, 138:1310-1316.
173. Ulmer A., Schmidt-Kittler O., Fischer J., Ellwanger U., Rassner G., Riethmuller G., Fierlbeck G., Klein C.A. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 2004, 10:531-537.
174. van der Pol J.P., Jager M.J., de Wolff-Rouendaal D., Ringens P.J., Vennegoor C., Ruiter D.J. Heterogeneous expression of melanoma-associated antigens in uveal melanomas. Curr. Eye Res. 1987, 6:757-765.
175. Vergilis I.J., Szarek M., Ferrone S., Reynolds S.R. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J. Invest. Dermatol. 2005, 125:526-531.
176. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
177. Wagner S., Hafner C., Allwardt D., Jasinska J., Ferrone S., Zielinski C.C., Scheiner O., Wiedermann U., Pehamberger H., Breiteneder H. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J. Immunol. 2005, 174:976-982.
178. Wagner S., Krepler C., Allwardt D., Latzka J., Strommer S., Scheiner O., Pehamberger H., Wiedermann U., Hafner C., Breiteneder H. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin. Cancer Res. 2008, 14:8178-8183.
179. Wang X., Osada T., Wang Y., Yu L., Sakakura K., Katayama A., McCarthy J., Brufsky A., Chivukula M., Khoury T., Hsu D., Lyerly H., Clay T., Ferrone S. CSPG4 protein as a new target for antibody-based immunotherapy of triple negative breast cancer 2010, J. Natl. Cancer Inst., (In press).
180. Wang X., Wang Y., Yu L., Sakakura K., Visus C., Schwab J.H., Ferrone C.R., Favoino E., Koya Y., Campoli M.R., McCarthy J.B., DeLeo A.B., Ferrone S. CSPG4 in cancer: Multiple roles. Curr. Mol. Med. 2010, 10:419-429.
181. Weed S.A., Parsons J.T. Cortactin: Coupling membrane dynamics to cortical actin assembly. Oncogene 2001, 20:6418-6434.
182. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
183. Wen Y., Makagiansar I.T., Fukushi J., Liu F.T., Fukuda M.N., Stallcup W.B. Molecular basis of interaction between NG2 proteoglycan and galectin-3. J. Cell. Biochem. 2006, 98:115-127.
184. Williams L.M., Lali F., Willetts K., Balague C., Godessart N., Brennan F., Feldmann M., Foxwell B.M. Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol. Immunol. 2008, 45:2446-2454.
185. Wuchter C., Harbott J., Schoch C., Schnittger S., Borkhardt A., Karawajew L., Ratei R., Ruppert V., Haferlach T., Creutzig U., Dorken B., Ludwig W.D. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 2000, 14:1232-1238.
186. Yang J., Price M.A., Neudauer C.L., Wilson C., Ferrone S., Xia H., Iida J., Simpson M.A., McCarthy J.B. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J. Cell Biol. 2004, 165:881-891.
187. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002, 99:16168-16173.
188. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.